<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03063086</url>
  </required_header>
  <id_info>
    <org_study_id>CQVM149B2208</org_study_id>
    <nct_id>NCT03063086</nct_id>
  </id_info>
  <brief_title>Assess Bronchodilator Effect and Safety of Two Doses of QVM149 Compared to a Fixed Dose Combination of Salmeterol/Fluticasone in Patients With Asthma.</brief_title>
  <official_title>A Randomized, Double-blind, Double-dummy, Active-controlled, 3-period Complete Cross-over Study to Assess the Bronchodilator Effect and Safety of Two Doses of QVM149 Compared to a Fixed Dose Combination of Salmeterol/Fluticasone in Patients With Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess peak FEV1 of two doses of QVM149 compared to a
      fixed-dose combination of salmeterol/fluticasone (50/500μg b.i.d.) and to characterize the
      respective 24 hour bronchodilator effect profiles in patients with asthma. Data from this
      study will complement lung function data obtained in the pivotal QVM149 phase 3 program by
      assessing the bronchodilatory effect of QVM149 at multiple time-points over an entire dosing
      interval of 24 hours.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 21, 2017</start_date>
  <completion_date type="Actual">August 2, 2018</completion_date>
  <primary_completion_date type="Actual">August 2, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak FEV1 (L) Defined as the Highest Bronchodilatory Effect on FEV1 During a Period of 5 Min to 4 h After the Last Evening Dose of Each Treatment Period</measure>
    <time_frame>3 weeks</time_frame>
    <description>The highest bronchodilator effect on FEV1 during a period of 5 min to 4 h after the last evening dose of each treatment period . To demonstrate superiority in peak bronchodilator effect of QVM149 at a dose of 150/50/160 μg o.d. and 150/50/80 μg o.d. compared to a FDC of salmeterol/fluticasone at a dose of 50/500 μg b.i.d. after 3 weeks of treatment in patients with asthma</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>FEV1 Over 24 h After 21 Days of Treatment in Relation to Evening Dose</measure>
    <time_frame>-45 min, -15 min, 5 min, 15 min, 30 min, 1 h, 2 h, 3h, 4 h, 8 h, 10 h, 11 h 55 min, 14 h, 18 h, 21 h, 23 h 15 min, 23 h 45 min at 3 weeks</time_frame>
    <description>To evaluate the bronchodilator effect of each dose of QVM149 compared to salmeterol/fluticasone FDC after 3 weeks of treatment at -45 min, -15 min, 5 min, 15 min, 30 min, 1 h, 2 h, 3h, 4 h, 8 h, 10 h, 11 h 55 min, 14 h, 18 h, 21 h, 23 h 15 min, 23 h 45 min.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC Over 24 h After 21 Days of Treatment in Relation to Evening Dose</measure>
    <time_frame>-45 min, -15 min, 5 min, 15 min, 30 min, 1 h, 2 h, 3h, 4 h, 8 h, 10 h, 11 h 55 min, 14 h, 18 h, 21 h, 23 h 15 min, 23 h 45 min at 3 weeks</time_frame>
    <description>To evaluate the bronchodilator effect of each dose of QVM149 compared to salmeterol/fluticasone FDC after 3 weeks of treatment at -45 min, -15 min, 5 min, 15 min, 30 min, 1 h, 2 h, 3h, 4 h, 8 h, 10 h, 11 h 55 min, 14 h, 18 h, 21 h, 23 h 15 min, 23 h 45 min.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1/FVC Ratio Over 24 h After 21 Days of Treatment in Relation to Evening Dose</measure>
    <time_frame>-45 min, -15 min, 5 min, 15 min, 30 min, 1 h, 2 h, 3h, 4 h, 8 h, 10 h, 11 h 55 min, 14 h, 18 h, 21 h, 23 h 15 min, 23 h 45 min at 3 weeks</time_frame>
    <description>To evaluate the bronchodilator effect of each dose of QVM149 compared to salmeterol/fluticasone FDC after 3 weeks of treatment at -45 min, -15 min, 5 min, 15 min, 30 min, 1 h, 2 h, 3h, 4 h, 8 h, 10 h, 11 h 55 min, 14 h, 18 h, 21 h, 23 h 15 min, 23 h 45 min.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 AUC 5 Min - 1 h (Day 21) FEV1 AUC 5 Min - 4 h (Day 21) and FEV1 AUC 5 Min - 23 h 45 Min (Day 21)</measure>
    <time_frame>3 weeks</time_frame>
    <description>To evaluate the bronchodilator effect of each dose of QVM149 compared to salmeterol/ fluticasone FDC by measuring standardized FEV1 AUCs after 3 weeks of treatment respective period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough FEV1 After 21 Days of Treatment</measure>
    <time_frame>3 weeks</time_frame>
    <description>To evaluate post-dose trough bronchodilator effect of each dose of QVM149 compared to salmeterol/fluticasone FDC after 3 weeks of treatment in the respective treatment period. The trough FEV1 is the mean value of FEV1 at 23 h 15 min and 23 h 45 min post-dose</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">116</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A-B-C</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A-C-B</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>B-C-A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>B-A-C</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 5</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>C-A-B</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 6</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>C-B-A</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>QVM149 150/50/80 μg o.d.</intervention_name>
    <description>A</description>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_label>Sequence 3</arm_group_label>
    <arm_group_label>Sequence 4</arm_group_label>
    <arm_group_label>Sequence 5</arm_group_label>
    <arm_group_label>Sequence 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>QVM149 150/50/160 μg o.d.</intervention_name>
    <description>B</description>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_label>Sequence 3</arm_group_label>
    <arm_group_label>Sequence 4</arm_group_label>
    <arm_group_label>Sequence 5</arm_group_label>
    <arm_group_label>Sequence 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>salmeterol/fluticasone FDC 50/500 μg b.i.d.</intervention_name>
    <description>C</description>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_label>Sequence 3</arm_group_label>
    <arm_group_label>Sequence 4</arm_group_label>
    <arm_group_label>Sequence 5</arm_group_label>
    <arm_group_label>Sequence 6</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion criteria

          -  Male and female adult patients ≥ 18 years old and ≤ 75 years.

          -  Patients with a documented physician diagnosis of asthma for a period of at least 12
             months prior to Visit 1 (Screening).

          -  Patients who have used ICS and LABA combinations for asthma for at least 3 month and
             at a stable medium or high dose of ICS for at least 1 month prior to Visit 1
             (Screening).

          -  Pre-bronchodilator FEV1 of &lt; 80 % of the predicted normal value at screening Visit 1
             (spirometry will not be repeated at baseline prior to randomization).

          -  Patients who demonstrate an increase in FEV1 of ≥ 12 % and 200 mL after administration
             of 400 µg salbutamol/360 µg albuterol (or equivalent do se) at Visit 1 (Screening).
             All patients must perform a reversibility test at Visit 1 (Screening). If
             reversibility is not demonstrated at Visit 1 (Screening), then, reversibility testing
             may be repeated once during the screening period.

          -  If reversibility is not demonstrated at Visit 1 (retesting allowed once), patients
             must be screen failed. Spacer devices are not permitted during reversibility testing
             Key Exclusion criteria

          -  Patients who have smoked or inhaled tobacco products within the 6 month period prior
             to Visit 1

          -  Patients who have had an asthma attack/exacerbation requiring systemic steroids or
             hospitalization or emergency room visit within 6 weeks of Visit 1

          -  Patients with narrow-angle glaucoma, symptomatic benign prostatic hyperplasia (BPH) or
             bladder-neck obstruction or severe renal impairment or urinary retention

          -  Patients who have had a respiratory tract infection or asthma worsening within 4 weeks
             prior to Visit 1

          -  Patients with any chronic conditions affecting the upper respiratory tract

          -  Patients with a history of chronic lung diseases other than asthma, including (but not
             limited to) COPD, sarcoidosis, interstitial lung disease, cystic fibrosis, clinically
             significant bronchiectasis and active tuberculosis.

          -  Patients with Type I diabetes or uncontrolled Type II diabetes (HbA1c &gt;9% at
             screening).

          -  Patients who have a clinically significant ECG abnormality at Visit 1

          -  Patients with a history of hypersensitivity or intolerance to any of the study drugs
             (including excipients)

          -  Patients with narcolepsy and/or insomnia.

          -  Patients on Maintenance Immunotherapy (desensitization) for allergies for less than 3
             months prior to Visit 2 or patients on Maintenance Immunotherapy for more than 3
             months prior to Visit 2 but expected to change throughout the course of the study.

          -  Pregnant or nursing (lactating) women

          -  Women of child-bearing potential must use Highly effective contraception methods

          -  Patients who have discontinued LAMA therapy in the past for any safety, tolerability
             or perceived lack of efficacy reason.

          -  History of paradoxical bronchospasm in response to inhaled medicines.

          -  Patients with a history of clinically relevant bronchoconstriction upon repeated
             forced expiratory maneuvers.

          -  Patient with a serum potassium level below the laboratory limit of normal at
             screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sofia</city>
        <zip>1612</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chang Chun</city>
        <state>Jilin</state>
        <zip>130021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300192</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shanghai</city>
        <zip>200433</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Frankfurt</city>
        <zip>60596</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Grosshansdorf</city>
        <zip>22947</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wiesbaden</city>
        <zip>65187</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Groningen</city>
        <state>GZ</state>
        <zip>9713</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Manchester</city>
        <zip>M23 9QZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>China</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Romania</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>February 21, 2017</study_first_submitted>
  <study_first_submitted_qc>February 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 24, 2017</study_first_posted>
  <results_first_submitted>July 31, 2019</results_first_submitted>
  <results_first_submitted_qc>November 25, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">December 13, 2019</results_first_posted>
  <last_update_submitted>November 25, 2019</last_update_submitted>
  <last_update_submitted_qc>November 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluticasone</mesh_term>
    <mesh_term>Salmeterol Xinafoate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 6, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/86/NCT03063086/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 12, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/86/NCT03063086/Prot_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Sequence 1 (A-B-C)</title>
          <description>QVM149 150/50/80 μg o.d; QVM149 150/50/160 μg o.d; salmeterol/fluticasone FDC 50/500 μg b.i.d.</description>
        </group>
        <group group_id="P2">
          <title>Sequence 2(A-C-B)</title>
          <description>QVM149 150/50/80 μg o.d; salmeterol/fluticasone FDC 50/500 μg b.i.d.; QVM149 150/50/160 μg o.d;</description>
        </group>
        <group group_id="P3">
          <title>Sequence 3(B-C-A)</title>
          <description>QVM149 150/50/160 μg o.d; salmeterol/fluticasone FDC 50/500 μg b.i.d.; QVM149 150/50/80 μg o.d</description>
        </group>
        <group group_id="P4">
          <title>Sequence 4(B-A-C)</title>
          <description>QVM149 150/50/160 μg o.d; QVM149 150/50/80 μg o.d; salmeterol/fluticasone FDC 50/500 μg b.i.d</description>
        </group>
        <group group_id="P5">
          <title>Sequence 5(C-A-B)</title>
          <description>salmeterol/fluticasone FDC 50/500 μg b.i.d; QVM149 150/50/80 μg o.d; QVM149 150/50/160 μg o.d</description>
        </group>
        <group group_id="P6">
          <title>Sequence 6(C-B-A)</title>
          <description>salmeterol/fluticasone FDC 50/500 μg b.i.d.; QVM149 150/50/160 μg o.d; QVM149 150/50/80 μg o.d</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="18"/>
                <participants group_id="P4" count="20"/>
                <participants group_id="P5" count="20"/>
                <participants group_id="P6" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="17"/>
                <participants group_id="P4" count="17"/>
                <participants group_id="P5" count="20"/>
                <participants group_id="P6" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>technical problems</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>subject/guardian decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance with study treatment</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Participants</title>
          <description>All participants randomized to one of six treatment sequences</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="116"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.5" spread="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="106"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Peak FEV1 (L) Defined as the Highest Bronchodilatory Effect on FEV1 During a Period of 5 Min to 4 h After the Last Evening Dose of Each Treatment Period</title>
        <description>The highest bronchodilator effect on FEV1 during a period of 5 min to 4 h after the last evening dose of each treatment period . To demonstrate superiority in peak bronchodilator effect of QVM149 at a dose of 150/50/160 μg o.d. and 150/50/80 μg o.d. compared to a FDC of salmeterol/fluticasone at a dose of 50/500 μg b.i.d. after 3 weeks of treatment in patients with asthma</description>
        <time_frame>3 weeks</time_frame>
        <population>Pharmacodynamics set - The PD analysis set included all patients with any available PD data, who received any study treatment and experienced no protocol deviations with relevant impact on PD data.</population>
        <group_list>
          <group group_id="O1">
            <title>QVM149 150/50/160 μg o.d.</title>
            <description>QVM149 150/50/160 μg o.d.</description>
          </group>
          <group group_id="O2">
            <title>QVM149 150/50/80 μg o.d.</title>
            <description>QVM149 150/50/80 μg o.d.</description>
          </group>
          <group group_id="O3">
            <title>Salmeterol/Fluticasone 50/500 µg b.i.d</title>
            <description>salmeterol/fluticasone 50/500 µg b.i.d</description>
          </group>
        </group_list>
        <measure>
          <title>Peak FEV1 (L) Defined as the Highest Bronchodilatory Effect on FEV1 During a Period of 5 Min to 4 h After the Last Evening Dose of Each Treatment Period</title>
          <description>The highest bronchodilator effect on FEV1 during a period of 5 min to 4 h after the last evening dose of each treatment period . To demonstrate superiority in peak bronchodilator effect of QVM149 at a dose of 150/50/160 μg o.d. and 150/50/80 μg o.d. compared to a FDC of salmeterol/fluticasone at a dose of 50/500 μg b.i.d. after 3 weeks of treatment in patients with asthma</description>
          <population>Pharmacodynamics set - The PD analysis set included all patients with any available PD data, who received any study treatment and experienced no protocol deviations with relevant impact on PD data.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
                <count group_id="O2" value="115"/>
                <count group_id="O3" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.792" spread="0.0750"/>
                    <measurement group_id="O2" value="2.779" spread="0.0750"/>
                    <measurement group_id="O3" value="2.620" spread="0.0750"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.172</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.137</ci_lower_limit>
            <ci_upper_limit>0.208</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>0.159</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.123</ci_lower_limit>
            <ci_upper_limit>0.195</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 Over 24 h After 21 Days of Treatment in Relation to Evening Dose</title>
        <description>To evaluate the bronchodilator effect of each dose of QVM149 compared to salmeterol/fluticasone FDC after 3 weeks of treatment at -45 min, -15 min, 5 min, 15 min, 30 min, 1 h, 2 h, 3h, 4 h, 8 h, 10 h, 11 h 55 min, 14 h, 18 h, 21 h, 23 h 15 min, 23 h 45 min.</description>
        <time_frame>-45 min, -15 min, 5 min, 15 min, 30 min, 1 h, 2 h, 3h, 4 h, 8 h, 10 h, 11 h 55 min, 14 h, 18 h, 21 h, 23 h 15 min, 23 h 45 min at 3 weeks</time_frame>
        <population>Pharmacodynamics set - The PD analysis set included all patients with any available PD data, who received any study treatment and experienced no protocol deviations with relevant impact on PD data.</population>
        <group_list>
          <group group_id="O1">
            <title>QVM149 150/50/160 μg o.d.</title>
            <description>QVM149 150/50/160 μg o.d.</description>
          </group>
          <group group_id="O2">
            <title>QVM149 150/50/80 μg o.d.</title>
            <description>QVM149 150/50/80 μg o.d.</description>
          </group>
          <group group_id="O3">
            <title>Salmeterol/Fluticasone 50/500 µg b.i.d</title>
            <description>salmeterol/fluticasone 50/500 µg b.i.d</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 Over 24 h After 21 Days of Treatment in Relation to Evening Dose</title>
          <description>To evaluate the bronchodilator effect of each dose of QVM149 compared to salmeterol/fluticasone FDC after 3 weeks of treatment at -45 min, -15 min, 5 min, 15 min, 30 min, 1 h, 2 h, 3h, 4 h, 8 h, 10 h, 11 h 55 min, 14 h, 18 h, 21 h, 23 h 15 min, 23 h 45 min.</description>
          <population>Pharmacodynamics set - The PD analysis set included all patients with any available PD data, who received any study treatment and experienced no protocol deviations with relevant impact on PD data.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
                <count group_id="O2" value="115"/>
                <count group_id="O3" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>-45 min</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="111"/>
                    <count group_id="O2" value="111"/>
                    <count group_id="O3" value="111"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6237" spread="0.07505"/>
                    <measurement group_id="O2" value="2.5639" spread="0.07503"/>
                    <measurement group_id="O3" value="2.4931" spread="0.07505"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>-15 min</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="111"/>
                    <count group_id="O2" value="109"/>
                    <count group_id="O3" value="109"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6023" spread="0.07479"/>
                    <measurement group_id="O2" value="2.5630" spread="0.07478"/>
                    <measurement group_id="O3" value="2.4835" spread="0.07480"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 min</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="110"/>
                    <count group_id="O2" value="108"/>
                    <count group_id="O3" value="109"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6412" spread="0.07446"/>
                    <measurement group_id="O2" value="2.6179" spread="0.07445"/>
                    <measurement group_id="O3" value="2.5035" spread="0.07446"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 min</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="110"/>
                    <count group_id="O2" value="108"/>
                    <count group_id="O3" value="108"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6696" spread="0.07531"/>
                    <measurement group_id="O2" value="2.6137" spread="0.07532"/>
                    <measurement group_id="O3" value="2.5172" spread="0.07533"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 min</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="110"/>
                    <count group_id="O2" value="108"/>
                    <count group_id="O3" value="110"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6873" spread="0.07444"/>
                    <measurement group_id="O2" value="2.6504" spread="0.07444"/>
                    <measurement group_id="O3" value="2.5286" spread="0.07444"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="110"/>
                    <count group_id="O2" value="107"/>
                    <count group_id="O3" value="108"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6922" spread="0.07430"/>
                    <measurement group_id="O2" value="2.6825" spread="0.07431"/>
                    <measurement group_id="O3" value="2.5398" spread="0.07431"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="109"/>
                    <count group_id="O2" value="107"/>
                    <count group_id="O3" value="107"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7033" spread="0.07441"/>
                    <measurement group_id="O2" value="2.6996" spread="0.07443"/>
                    <measurement group_id="O3" value="2.5244" spread="0.07443"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="109"/>
                    <count group_id="O2" value="107"/>
                    <count group_id="O3" value="106"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6995" spread="0.07449"/>
                    <measurement group_id="O2" value="2.6719" spread="0.07450"/>
                    <measurement group_id="O3" value="2.5296" spread="0.07451"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="109"/>
                    <count group_id="O2" value="107"/>
                    <count group_id="O3" value="106"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6815" spread="0.07482"/>
                    <measurement group_id="O2" value="2.6565" spread="0.07484"/>
                    <measurement group_id="O3" value="2.5164" spread="0.07485"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="109"/>
                    <count group_id="O2" value="104"/>
                    <count group_id="O3" value="105"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6801" spread="0.07454"/>
                    <measurement group_id="O2" value="2.6550" spread="0.07459"/>
                    <measurement group_id="O3" value="2.4918" spread="0.07459"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="108"/>
                    <count group_id="O2" value="105"/>
                    <count group_id="O3" value="105"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6999" spread="0.07489"/>
                    <measurement group_id="O2" value="2.6796" spread="0.07494"/>
                    <measurement group_id="O3" value="2.4908" spread="0.07495"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>11h 55 min</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="107"/>
                    <count group_id="O2" value="104"/>
                    <count group_id="O3" value="103"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7042" spread="0.07486"/>
                    <measurement group_id="O2" value="2.6641" spread="0.07490"/>
                    <measurement group_id="O3" value="2.4841" spread="0.07491"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>14 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="107"/>
                    <count group_id="O2" value="103"/>
                    <count group_id="O3" value="103"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6829" spread="0.07456"/>
                    <measurement group_id="O2" value="2.6541" spread="0.07459"/>
                    <measurement group_id="O3" value="2.5354" spread="0.07461"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="107"/>
                    <count group_id="O2" value="102"/>
                    <count group_id="O3" value="102"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6345" spread="0.07451"/>
                    <measurement group_id="O2" value="2.6073" spread="0.07455"/>
                    <measurement group_id="O3" value="2.5329" spread="0.07457"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>21 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="107"/>
                    <count group_id="O2" value="102"/>
                    <count group_id="O3" value="100"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6113" spread="0.07466"/>
                    <measurement group_id="O2" value="2.5989" spread="0.07472"/>
                    <measurement group_id="O3" value="2.5133" spread="0.07475"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>23 h 15 min</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="105"/>
                    <count group_id="O2" value="100"/>
                    <count group_id="O3" value="100"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6143" spread="0.07433"/>
                    <measurement group_id="O2" value="2.5950" spread="0.07438"/>
                    <measurement group_id="O3" value="2.4854" spread="0.07439"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>23 h 45 min</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="105"/>
                    <count group_id="O2" value="99"/>
                    <count group_id="O3" value="100"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5966" spread="0.07433"/>
                    <measurement group_id="O2" value="2.5722" spread="0.07438"/>
                    <measurement group_id="O3" value="2.4913" spread="0.07439"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FVC Over 24 h After 21 Days of Treatment in Relation to Evening Dose</title>
        <description>To evaluate the bronchodilator effect of each dose of QVM149 compared to salmeterol/fluticasone FDC after 3 weeks of treatment at -45 min, -15 min, 5 min, 15 min, 30 min, 1 h, 2 h, 3h, 4 h, 8 h, 10 h, 11 h 55 min, 14 h, 18 h, 21 h, 23 h 15 min, 23 h 45 min.</description>
        <time_frame>-45 min, -15 min, 5 min, 15 min, 30 min, 1 h, 2 h, 3h, 4 h, 8 h, 10 h, 11 h 55 min, 14 h, 18 h, 21 h, 23 h 15 min, 23 h 45 min at 3 weeks</time_frame>
        <population>Pharmacodynamics set - The PD analysis set included all patients with any available PD data, who received any study treatment and experienced no protocol deviations with relevant impact on PD data.</population>
        <group_list>
          <group group_id="O1">
            <title>QVM149 150/50/160 μg o.d.</title>
            <description>QVM149 150/50/160 μg o.d.</description>
          </group>
          <group group_id="O2">
            <title>QVM149 150/50/80 μg o.d.</title>
            <description>QVM149 150/50/80 μg o.d.</description>
          </group>
          <group group_id="O3">
            <title>Salmeterol/Fluticasone 50/500 μg b.i.d</title>
            <description>Salmeterol/fluticasone 50/500 μg b.i.d</description>
          </group>
        </group_list>
        <measure>
          <title>FVC Over 24 h After 21 Days of Treatment in Relation to Evening Dose</title>
          <description>To evaluate the bronchodilator effect of each dose of QVM149 compared to salmeterol/fluticasone FDC after 3 weeks of treatment at -45 min, -15 min, 5 min, 15 min, 30 min, 1 h, 2 h, 3h, 4 h, 8 h, 10 h, 11 h 55 min, 14 h, 18 h, 21 h, 23 h 15 min, 23 h 45 min.</description>
          <population>Pharmacodynamics set - The PD analysis set included all patients with any available PD data, who received any study treatment and experienced no protocol deviations with relevant impact on PD data.</population>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
                <count group_id="O2" value="115"/>
                <count group_id="O3" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>-45min</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="111"/>
                    <count group_id="O2" value="110"/>
                    <count group_id="O3" value="110"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9046" spread="1.03169"/>
                    <measurement group_id="O2" value="3.8538" spread="0.98086"/>
                    <measurement group_id="O3" value="3.7626" spread="1.00067"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>-15min</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="111"/>
                    <count group_id="O2" value="109"/>
                    <count group_id="O3" value="108"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8743" spread="1.04318"/>
                    <measurement group_id="O2" value="3.8571" spread="0.97420"/>
                    <measurement group_id="O3" value="3.7230" spread="0.94180"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5min</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="110"/>
                    <count group_id="O2" value="107"/>
                    <count group_id="O3" value="107"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8656" spread="0.99877"/>
                    <measurement group_id="O2" value="3.8976" spread="1.00323"/>
                    <measurement group_id="O3" value="3.7536" spread="0.93696"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15min</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="110"/>
                    <count group_id="O2" value="107"/>
                    <count group_id="O3" value="106"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8669" spread="0.98489"/>
                    <measurement group_id="O2" value="3.8971" spread="0.96840"/>
                    <measurement group_id="O3" value="3.7290" spread="0.94033"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30min</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="109"/>
                    <count group_id="O2" value="108"/>
                    <count group_id="O3" value="108"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8700" spread="0.99289"/>
                    <measurement group_id="O2" value="3.9002" spread="0.99091"/>
                    <measurement group_id="O3" value="3.7695" spread="0.96026"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="109"/>
                    <count group_id="O2" value="107"/>
                    <count group_id="O3" value="107"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8756" spread="0.99978"/>
                    <measurement group_id="O2" value="3.8993" spread="0.99141"/>
                    <measurement group_id="O3" value="3.7530" spread="0.97083"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="108"/>
                    <count group_id="O2" value="107"/>
                    <count group_id="O3" value="107"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8698" spread="0.99623"/>
                    <measurement group_id="O2" value="3.8985" spread="0.99369"/>
                    <measurement group_id="O3" value="3.7629" spread="0.97164"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="109"/>
                    <count group_id="O2" value="106"/>
                    <count group_id="O3" value="105"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8576" spread="0.98598"/>
                    <measurement group_id="O2" value="3.8766" spread="0.97806"/>
                    <measurement group_id="O3" value="3.7575" spread="0.96899"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="109"/>
                    <count group_id="O2" value="107"/>
                    <count group_id="O3" value="106"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8744" spread="0.99833"/>
                    <measurement group_id="O2" value="3.8627" spread="0.95673"/>
                    <measurement group_id="O3" value="3.7629" spread="0.98205"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="109"/>
                    <count group_id="O2" value="103"/>
                    <count group_id="O3" value="105"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9020" spread="0.98241"/>
                    <measurement group_id="O2" value="3.9217" spread="0.99184"/>
                    <measurement group_id="O3" value="3.7683" spread="1.00410"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="108"/>
                    <count group_id="O2" value="103"/>
                    <count group_id="O3" value="105"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8976" spread="0.98360"/>
                    <measurement group_id="O2" value="3.9504" spread="0.99286"/>
                    <measurement group_id="O3" value="3.7809" spread="0.98213"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>11h 55min</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="107"/>
                    <count group_id="O2" value="102"/>
                    <count group_id="O3" value="102"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9271" spread="0.98924"/>
                    <measurement group_id="O2" value="3.9405" spread="1.00198"/>
                    <measurement group_id="O3" value="3.7911" spread="0.99102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>14h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="107"/>
                    <count group_id="O2" value="103"/>
                    <count group_id="O3" value="103"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9091" spread="1.00241"/>
                    <measurement group_id="O2" value="3.9210" spread="0.97942"/>
                    <measurement group_id="O3" value="3.8089" spread="1.02918"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="107"/>
                    <count group_id="O2" value="102"/>
                    <count group_id="O3" value="101"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8675" spread="0.95725"/>
                    <measurement group_id="O2" value="3.9151" spread="1.02198"/>
                    <measurement group_id="O3" value="3.7824" spread="0.98395"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>21h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="107"/>
                    <count group_id="O2" value="101"/>
                    <count group_id="O3" value="100"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8438" spread="1.00672"/>
                    <measurement group_id="O2" value="3.8694" spread="0.98786"/>
                    <measurement group_id="O3" value="3.7680" spread="1.00768"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>23h 15min</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="104"/>
                    <count group_id="O2" value="100"/>
                    <count group_id="O3" value="100"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7997" spread="0.97550"/>
                    <measurement group_id="O2" value="3.8673" spread="0.99915"/>
                    <measurement group_id="O3" value="3.7395" spread="1.01764"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>23h 45min</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="105"/>
                    <count group_id="O2" value="99"/>
                    <count group_id="O3" value="98"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8034" spread="0.99036"/>
                    <measurement group_id="O2" value="3.8603" spread="0.98502"/>
                    <measurement group_id="O3" value="3.7431" spread="1.00668"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1/FVC Ratio Over 24 h After 21 Days of Treatment in Relation to Evening Dose</title>
        <description>To evaluate the bronchodilator effect of each dose of QVM149 compared to salmeterol/fluticasone FDC after 3 weeks of treatment at -45 min, -15 min, 5 min, 15 min, 30 min, 1 h, 2 h, 3h, 4 h, 8 h, 10 h, 11 h 55 min, 14 h, 18 h, 21 h, 23 h 15 min, 23 h 45 min.</description>
        <time_frame>-45 min, -15 min, 5 min, 15 min, 30 min, 1 h, 2 h, 3h, 4 h, 8 h, 10 h, 11 h 55 min, 14 h, 18 h, 21 h, 23 h 15 min, 23 h 45 min at 3 weeks</time_frame>
        <population>Pharmacodynamics set - The PD analysis set included all patients with any available PD data, who received any study treatment and experienced no protocol deviations with relevant impact on PD data.</population>
        <group_list>
          <group group_id="O1">
            <title>QVM149 150/50/160 μg o.d.</title>
            <description>QVM149 150/50/160 μg o.d.</description>
          </group>
          <group group_id="O2">
            <title>QVM149 150/50/80 μg o.d.</title>
            <description>QVM149 150/50/80 μg o.d.</description>
          </group>
          <group group_id="O3">
            <title>Salmeterol/Fluticasone 50/500 μg b.i.d</title>
            <description>Salmeterol/fluticasone 50/500 μg b.i.d</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1/FVC Ratio Over 24 h After 21 Days of Treatment in Relation to Evening Dose</title>
          <description>To evaluate the bronchodilator effect of each dose of QVM149 compared to salmeterol/fluticasone FDC after 3 weeks of treatment at -45 min, -15 min, 5 min, 15 min, 30 min, 1 h, 2 h, 3h, 4 h, 8 h, 10 h, 11 h 55 min, 14 h, 18 h, 21 h, 23 h 15 min, 23 h 45 min.</description>
          <population>Pharmacodynamics set - The PD analysis set included all patients with any available PD data, who received any study treatment and experienced no protocol deviations with relevant impact on PD data.</population>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
                <count group_id="O2" value="115"/>
                <count group_id="O3" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>-45min</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="107"/>
                    <count group_id="O2" value="107"/>
                    <count group_id="O3" value="108"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6701" spread="0.10880"/>
                    <measurement group_id="O2" value="0.6612" spread="0.10358"/>
                    <measurement group_id="O3" value="0.6527" spread="0.10867"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>-15min</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="107"/>
                    <count group_id="O2" value="106"/>
                    <count group_id="O3" value="108"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6707" spread="0.10646"/>
                    <measurement group_id="O2" value="0.6669" spread="0.10422"/>
                    <measurement group_id="O3" value="0.6539" spread="0.10526"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5min</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="109"/>
                    <count group_id="O2" value="106"/>
                    <count group_id="O3" value="103"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6788" spread="0.10300"/>
                    <measurement group_id="O2" value="0.6754" spread="0.10370"/>
                    <measurement group_id="O3" value="0.6563" spread="0.10639"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15min</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="106"/>
                    <count group_id="O2" value="103"/>
                    <count group_id="O3" value="103"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6873" spread="0.10126"/>
                    <measurement group_id="O2" value="0.6778" spread="0.10734"/>
                    <measurement group_id="O3" value="0.6560" spread="0.10823"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30min</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="106"/>
                    <count group_id="O2" value="103"/>
                    <count group_id="O3" value="108"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6878" spread="0.10137"/>
                    <measurement group_id="O2" value="0.6844" spread="0.10699"/>
                    <measurement group_id="O3" value="0.6573" spread="0.10552"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="108"/>
                    <count group_id="O2" value="106"/>
                    <count group_id="O3" value="105"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6900" spread="0.09764"/>
                    <measurement group_id="O2" value="0.6895" spread="0.09940"/>
                    <measurement group_id="O3" value="0.6632" spread="0.10403"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="107"/>
                    <count group_id="O2" value="105"/>
                    <count group_id="O3" value="106"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6939" spread="0.09629"/>
                    <measurement group_id="O2" value="0.6932" spread="0.10073"/>
                    <measurement group_id="O3" value="0.6647" spread="0.10413"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="108"/>
                    <count group_id="O2" value="106"/>
                    <count group_id="O3" value="104"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6968" spread="0.10159"/>
                    <measurement group_id="O2" value="0.6890" spread="0.10052"/>
                    <measurement group_id="O3" value="0.6634" spread="0.10436"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="106"/>
                    <count group_id="O2" value="107"/>
                    <count group_id="O3" value="105"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6897" spread="0.10060"/>
                    <measurement group_id="O2" value="0.6879" spread="0.09733"/>
                    <measurement group_id="O3" value="0.6605" spread="0.10419"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="105"/>
                    <count group_id="O2" value="95"/>
                    <count group_id="O3" value="102"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6842" spread="0.10782"/>
                    <measurement group_id="O2" value="0.6802" spread="0.11349"/>
                    <measurement group_id="O3" value="0.6492" spread="0.10814"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="105"/>
                    <count group_id="O2" value="99"/>
                    <count group_id="O3" value="104"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6916" spread="0.10550"/>
                    <measurement group_id="O2" value="0.6858" spread="0.10468"/>
                    <measurement group_id="O3" value="0.6489" spread="0.11155"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>11h 55min</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="103"/>
                    <count group_id="O2" value="99"/>
                    <count group_id="O3" value="102"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6853" spread="0.10672"/>
                    <measurement group_id="O2" value="0.6791" spread="0.10656"/>
                    <measurement group_id="O3" value="0.6482" spread="0.10810"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>14h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="104"/>
                    <count group_id="O2" value="101"/>
                    <count group_id="O3" value="101"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6846" spread="0.10842"/>
                    <measurement group_id="O2" value="0.6848" spread="0.10450"/>
                    <measurement group_id="O3" value="0.6567" spread="0.11048"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="104"/>
                    <count group_id="O2" value="101"/>
                    <count group_id="O3" value="97"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6801" spread="0.09943"/>
                    <measurement group_id="O2" value="0.6741" spread="0.10240"/>
                    <measurement group_id="O3" value="0.6546" spread="0.10369"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>21h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="106"/>
                    <count group_id="O2" value="99"/>
                    <count group_id="O3" value="99"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6790" spread="0.10890"/>
                    <measurement group_id="O2" value="0.6785" spread="0.10387"/>
                    <measurement group_id="O3" value="0.6562" spread="0.10729"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>23h 15min</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="102"/>
                    <count group_id="O2" value="98"/>
                    <count group_id="O3" value="100"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="06821" spread="0.10386"/>
                    <measurement group_id="O2" value="0.6791" spread="0.09986"/>
                    <measurement group_id="O3" value="0.6548" spread="0.10423"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>23h 45min</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="104"/>
                    <count group_id="O2" value="98"/>
                    <count group_id="O3" value="98"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6782" spread="0.10457"/>
                    <measurement group_id="O2" value="0.6776" spread="0.10111"/>
                    <measurement group_id="O3" value="0.6537" spread="0.10934"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 AUC 5 Min - 1 h (Day 21) FEV1 AUC 5 Min - 4 h (Day 21) and FEV1 AUC 5 Min - 23 h 45 Min (Day 21)</title>
        <description>To evaluate the bronchodilator effect of each dose of QVM149 compared to salmeterol/ fluticasone FDC by measuring standardized FEV1 AUCs after 3 weeks of treatment respective period.</description>
        <time_frame>3 weeks</time_frame>
        <population>Pharmacodynamics set - The PD analysis set included all patients with any available PD data, who received any study treatment and experienced no protocol deviations with relevant impact on PD data.</population>
        <group_list>
          <group group_id="O1">
            <title>QVM149 150/50/160 μg o.d.</title>
            <description>QVM149 150/50/160 μg o.d.</description>
          </group>
          <group group_id="O2">
            <title>QVM149 150/50/80 μg o.d.</title>
            <description>QVM149 150/50/80 μg o.d.</description>
          </group>
          <group group_id="O3">
            <title>Salmeterol/Fluticasone 50/500 µg b.i.d</title>
            <description>salmeterol/fluticasone 50/500 µg b.i.d</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 AUC 5 Min - 1 h (Day 21) FEV1 AUC 5 Min - 4 h (Day 21) and FEV1 AUC 5 Min - 23 h 45 Min (Day 21)</title>
          <description>To evaluate the bronchodilator effect of each dose of QVM149 compared to salmeterol/ fluticasone FDC by measuring standardized FEV1 AUCs after 3 weeks of treatment respective period.</description>
          <population>Pharmacodynamics set - The PD analysis set included all patients with any available PD data, who received any study treatment and experienced no protocol deviations with relevant impact on PD data.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
                <count group_id="O2" value="115"/>
                <count group_id="O3" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>FEV1 AUC 5 min - 1 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="108"/>
                    <count group_id="O2" value="103"/>
                    <count group_id="O3" value="100"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.673" spread="0.0735"/>
                    <measurement group_id="O2" value="2.644" spread="0.0736"/>
                    <measurement group_id="O3" value="2.513" spread="0.0737"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FEV1 AUC 5 min - 4 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="104"/>
                    <count group_id="O2" value="104"/>
                    <count group_id="O3" value="99"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.687" spread="0.0741"/>
                    <measurement group_id="O2" value="2.669" spread="0.0741"/>
                    <measurement group_id="O3" value="2.510" spread="0.0742"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FEV1 AUC 5 min - 23 h 45 min</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="101"/>
                    <count group_id="O2" value="93"/>
                    <count group_id="O3" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.677" spread="0.0766"/>
                    <measurement group_id="O2" value="2.652" spread="0.0768"/>
                    <measurement group_id="O3" value="2.515" spread="0.0768"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough FEV1 After 21 Days of Treatment</title>
        <description>To evaluate post-dose trough bronchodilator effect of each dose of QVM149 compared to salmeterol/fluticasone FDC after 3 weeks of treatment in the respective treatment period. The trough FEV1 is the mean value of FEV1 at 23 h 15 min and 23 h 45 min post-dose</description>
        <time_frame>3 weeks</time_frame>
        <population>Pharmacodynamics set - The PD analysis set included all patients with any available PD data, who received any study treatment and experienced no protocol deviations with relevant impact on PD data</population>
        <group_list>
          <group group_id="O1">
            <title>QVM149 150/50/160 μg o.d.</title>
            <description>QVM149 150/50/160 μg o.d.</description>
          </group>
          <group group_id="O2">
            <title>QVM149 150/50/80 μg o.d.</title>
            <description>QVM149 150/50/80 μg o.d.</description>
          </group>
          <group group_id="O3">
            <title>Salmeterol/Fluticasone 50/500 µg b.i.d</title>
            <description>salmeterol/fluticasone 50/500 µg b.i.d</description>
          </group>
        </group_list>
        <measure>
          <title>Trough FEV1 After 21 Days of Treatment</title>
          <description>To evaluate post-dose trough bronchodilator effect of each dose of QVM149 compared to salmeterol/fluticasone FDC after 3 weeks of treatment in the respective treatment period. The trough FEV1 is the mean value of FEV1 at 23 h 15 min and 23 h 45 min post-dose</description>
          <population>Pharmacodynamics set - The PD analysis set included all patients with any available PD data, who received any study treatment and experienced no protocol deviations with relevant impact on PD data</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
                <count group_id="O2" value="115"/>
                <count group_id="O3" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.623" spread="0.0756"/>
                    <measurement group_id="O2" value="2.6046" spread="0.0757"/>
                    <measurement group_id="O3" value="2.4998" spread="0.0757"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.124</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.086</ci_lower_limit>
            <ci_upper_limit>0.161</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 22 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>QVM149 150/50/160 µg o.d.</title>
          <description>QVM149 150/50/160 µg o.d.</description>
        </group>
        <group group_id="E2">
          <title>QVM149 150/50/80 µg o.d.</title>
          <description>QVM149 150/50/80 µg o.d.</description>
        </group>
        <group group_id="E3">
          <title>Salmeterol/Fluticasone 50/500 µg b.i.d.</title>
          <description>Salmeterol/fluticasone 50/500 µg b.i.d.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (21.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862-778-8300</phone>
      <email>novartis.email@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

